MedTrace Logo

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

NCT01446718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2019-07-05

No results posted yet for this study

Summary

The purpose of this study is to determine sustained immunogenicity of the quadrivalent vaccine 'Gardasil', 48 months after initial vaccination, among HIV-1 infected boys and girls age 9-14 years. This age range is within the World Health Organization (WHO) stipulated guidelines for national programs for the vaccine.

Conditions

  • Human Papillomavirus
  • HIV-1 Infection

Interventions

BIOLOGICAL

Gardasil vaccine

0.5ml of intramuscular vaccine in three doses

Sponsors & Collaborators

Principal Investigators

  • Nelly R Mugo, MMed, MPH · Kenya Medical Research Institute

Eligibility

Min Age
9 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-15
Primary Completion
2018-06-30
Completion
2018-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01446718 on ClinicalTrials.gov